Global Polycystic Ovary Syndrome Market is Segmented By Treatment( Drug Class, Contraceptives, Insulin-sensitizing Agent, Antidepressants, Anti-obesity, Other Drug Classes), Surgery(Ovarian Wedge Resection, Laparoscopic Ovarian Drilling, Other Surgeries), By End-user(Hospitals, Specialty Clinics, Others), By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Polycystic Ovary Syndrome Market Overview
The Global Polycystic Ovary Syndrome Market reached USD 3.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.6 billion by 2030. The Global Polycystic Ovary Syndrome Market is expected to exhibit a CAGR of 5.5% during the forecast period 2024-2031. The increasing cases of polycystic ovary syndrome, increase in the prevalence of risk factors, growing awareness, funding initiatives, increasing search activities, favorable reimbursement policies, and market developments such as product launches, product authorizations, alliances, acquisitions, coalitions, and expansion among others are expected to boost the Global Polycystic Ovary Syndrome Market growth in the forecast period. The key market players in this market include Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, and Takeda Pharmaceutical Company Limited, among others.
Polycystic Ovary Syndrome Market Scope
| Metrics | Details |
| CAGR | 5.5% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2023-2030 |
| Data Availability | Value (US$) |
| Segments Covered | Treatment Type, End-user |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To know more Insights - Download Sample
Polycystic Ovary Syndrome Market Dynamics
Increasing Market Developments Drive The Growth Of The Polycystic Ovary Syndrome Market
The increasing market developments, including product launches, approvals, collaborations, and mergers, are expected to boost the Global Polycystic Ovary Syndrome Market growth in the forecast period.
For instance, in January 2022, Celmatix Inc., a biotechnology corporation concentrated on ovarian biology, declared that a third landmark had been completed in its five-year, multi-target collaboration with Evotec, a publicly listed drug discovery and development corporation.
Evotec and Bayer AG initiated the milestone of progressing a PCOS drug program centered close to a novel Celmatix-identified drug target into hit identification.
Also, in June 2022, Bayer, a German multinational pharmaceutical and biotechnology corporation, inaugurated its brand-new Research and Innovation Center at Kendall Square in the United States, expanding the corporation's existence in one of the most cutting-edge pharmaceutical research and design headquarters.
Increasing Research Funding Are Expected To Present The Global Polycystic Ovary Syndrome Market With Growth Opportunities.
The increasing research funding from various government organizations is presenting the global polycystic ovary syndrome market with lucrative growth opportunities in the upcoming years. For instance, according to the NIH, estimates of funding for various Research, Condition, and Disease Categories (RCDC), USD 9 million were spent on polycystic ovary syndrome (PCOS) and estimated to spend USD 10 million in 2023 and 2024.
Side Effects of Treatment are Estimated To Hamper The Global Polycystic Ovary Syndrome Market During The Forecast Period.
The side effects caused by the polycystic ovary syndrome treatment are hampering the global market growth during the forecast period. For instance, the polycystic ovary syndrome treatment includes hypoglycemic agents, which can lead to gastrointestinal upset, lactic acidosis, increase in homocysteine levels, weight gain, congestive heart failure, and edema among other side effects associated with different treatment options.
Polycystic Ovary Syndrome Market Segment Analysis
The Global Polycystic Ovary Syndrome Market is segmented based on treatment type, end-user, and region.
The Drug Segment is Estimated to Dominate the Global Polycystic Ovary Syndrome Market.
Treatment outcomes are expected to contribute to the growth of the drug treatment segment enabling it to attain about 65.9% of the total market share by 2030. For instance, letrozole is a fertility drug that is rising in favor as a therapy choice for females with Polycystic Ovarian Syndrome (PCOS) since it has established so advantageous to those with PCOS that considerable fertility experts have left Clomid in the wayside for the near-exclusive usage of Letrozole as the go-to, first-line drug in aiding those with PCOS obtain pregnancy. Also, research has revealed that Letrozole can improve gestation and live birth rates for females with PCOS.
Source: DataM Intelligence Analysis (2023)
Polycystic Ovary Syndrome Market Geographical Penetration
North America is Estimated to hold Approximately 41.5% of the Market Share by 2030, Owing to The Increasing Prevalence and Awareness Initiatives in This Region.
Owing to the increasing prevalence of polycystic ovary syndrome and awareness initiatives, North America is estimated to dominate the global market, holding 41.5% of the worldwide market share.
For instance, in December 2022, the Centers for Disease Control and Prevention, the national public health agency of the U.S., publicized data, according to which polycystic ovary syndrome (PCOS) is among the standard reasons for female infertility, which impact over 6% to 12% accounting for around 5 million of the U.S. females of reproductive age.
Moreover, the PCOS Awareness Association, a dynamic non-profit organization that strives to break down barriers and provide educational services strives to raise multinational awareness of Polycystic Ovarian Syndrome (PCOS) and support those diagnosed with this disorder.
Source: DataM Intelligence Analysis (2023)
Polycystic Ovary Syndrome Market Competitive Landscape
The major global players in the polycystic ovary syndrome market include Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Limited, Novartis, Takeda Pharmaceutical Company Limited, Abbvie, Ferring BV, Merck KGaA, EffRx, Inc., among others.
COVID-19 Impact on Polycystic Ovary Syndrome Market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine brawl is considered to carry very little impact on the global polycystic ovary syndrome market, as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.
There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of fundamental materials are predicted to have a small influence on the global Polycystic Ovary Syndrome market growth in the forecast period.
By Treatment Type
- Drug Treatment
- Contraceptives
- Insulin-sensitizing Agent
- Antidepressants
- Anti-obesity
- Other Drug Classes
- Surgical Treatment
- Ovarian Wedge Resection
- Laparoscopic Ovarian Drilling
- Other Surgeries
By End-user
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- The U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- In December 2021, Organon, a global provider of women's healthcare, acquired Forendo Pharma, a firm specializing in clinical-stage pharmaceutical product development for women's health, including a polycystic ovarian syndrome-focused preclinical program of Forendo's pipeline (PCOS).
- In March 2022, Cipla Inc., a top multinational pharmaceutical corporation, introduced Evexpert intimate wash to grow the women’s feminine hygiene product portfolio.
- In February 2022, Dr. Reddy’s Laboratories Ltd., a top global pharmaceutical corporation, formed an exclusive sales and distribution contract with Novartis India Ltd., a multinational healthcare corporation planning to bolster its trademark existence in India and improve its customer base.
Why Purchase the Report?
- To visualize the Global Polycystic Ovary Syndrome Market segmentation based on treatment type, end-user, and region and understand critical commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous polycystic ovary syndrome market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Polycystic Ovary Syndrome Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
For more Pharmaceuticals related reports, please click here
